ES3038057T3 - Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere - Google Patents

Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere

Info

Publication number
ES3038057T3
ES3038057T3 ES20155920T ES20155920T ES3038057T3 ES 3038057 T3 ES3038057 T3 ES 3038057T3 ES 20155920 T ES20155920 T ES 20155920T ES 20155920 T ES20155920 T ES 20155920T ES 3038057 T3 ES3038057 T3 ES 3038057T3
Authority
ES
Spain
Prior art keywords
thio
pharmaceutical composition
cells
telomerase
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20155920T
Other languages
English (en)
Spanish (es)
Inventor
Jerry Shay
Sergei Gryaznov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
The University of Texas at Austin
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Application granted granted Critical
Publication of ES3038057T3 publication Critical patent/ES3038057T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biochemistry (AREA)
ES20155920T 2013-04-08 2014-04-08 Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere Active ES3038057T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361809575P 2013-04-08 2013-04-08

Publications (1)

Publication Number Publication Date
ES3038057T3 true ES3038057T3 (en) 2025-10-09

Family

ID=50819958

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20155920T Active ES3038057T3 (en) 2013-04-08 2014-04-08 Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere

Country Status (17)

Country Link
US (1) US10463685B2 (enExample)
EP (2) EP3682888B1 (enExample)
JP (1) JP6525956B2 (enExample)
KR (1) KR20150143587A (enExample)
CN (2) CN110339203A (enExample)
AU (1) AU2014251093B2 (enExample)
BR (1) BR112015025206A2 (enExample)
CA (1) CA2907924C (enExample)
ES (1) ES3038057T3 (enExample)
HK (1) HK1219418A1 (enExample)
HU (1) HUE072426T2 (enExample)
MX (1) MX387008B (enExample)
NZ (1) NZ713498A (enExample)
PL (1) PL3682888T3 (enExample)
RU (1) RU2713555C2 (enExample)
SG (2) SG10202002556QA (enExample)
WO (1) WO2014168947A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180036331A1 (en) * 2016-03-24 2018-02-08 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
EP3463370A4 (en) * 2016-05-27 2020-04-08 The Board of Regents of The University of Texas System 6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE-DEPENDENT TELOMER DYS FUNCTION AND CELL DEATH IN THERAPY-RESISTANT CANCER CELL
US20210023107A1 (en) * 2018-03-22 2021-01-28 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
AU2019208197B2 (en) 2018-07-31 2025-05-29 Howmedica Osteonics Corp. Fixation devices and prostheses for soft tissue connection to the same
CA3115712A1 (en) * 2018-10-17 2020-04-23 Xibin Liao 6-mercaptopurine nucleoside analogues
USD1046142S1 (en) 2019-07-24 2024-10-08 Howmedica Osteonics Corp. Proximal tibial prosthesis
CN112898292A (zh) 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
FI4117667T3 (fi) 2020-03-13 2025-02-10 Univ Texas Syöpien jaksottainen hoito käyttäen 6-tio-dg- ja tarkistuspisteen inhibiittoreita
CN120981470A (zh) * 2023-03-14 2025-11-18 浙江华海药业股份有限公司 一类核苷类似物及其应用
CN121002041A (zh) * 2023-03-14 2025-11-21 浙江华海药业股份有限公司 一类靶向端粒酶的核苷类似物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57209226A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
CA2444071C (en) 1991-02-08 2008-10-07 Wellstat Therapeutics Corporation Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
EP1879657A2 (en) 2005-04-25 2008-01-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
CN101220071B (zh) * 2008-01-17 2011-04-06 南京长澳医药科技有限公司 稳定的6-甲氧基-2’,3’-双脱氧鸟嘌呤核苷及其制备方法和包含它的药物组合物
US20100323979A1 (en) * 2009-06-16 2010-12-23 Weis-Amon Angelika B Methods and compositions for inhibiting proliferation of aneuploid cells

Also Published As

Publication number Publication date
CA2907924A1 (en) 2014-10-16
JP2016516773A (ja) 2016-06-09
US10463685B2 (en) 2019-11-05
WO2014168947A9 (en) 2014-12-31
NZ732228A (en) 2020-11-27
WO2014168947A3 (en) 2015-02-19
JP6525956B2 (ja) 2019-06-05
HK1219418A1 (zh) 2017-04-07
EP3682888B1 (en) 2025-06-11
PL3682888T3 (pl) 2025-09-22
WO2014168947A2 (en) 2014-10-16
SG10202002556QA (en) 2020-04-29
US20140303239A1 (en) 2014-10-09
MX2015014159A (es) 2016-06-21
KR20150143587A (ko) 2015-12-23
RU2713555C2 (ru) 2020-02-05
RU2015147555A (ru) 2017-05-15
AU2014251093B2 (en) 2017-06-15
CN105338987A (zh) 2016-02-17
CA2907924C (en) 2022-10-25
EP3682888A1 (en) 2020-07-22
HUE072426T2 (hu) 2025-11-28
SG11201508336TA (en) 2015-11-27
AU2014251093A1 (en) 2015-10-15
MX387008B (es) 2025-03-19
BR112015025206A2 (pt) 2017-07-18
CN110339203A (zh) 2019-10-18
EP2983675A2 (en) 2016-02-17
NZ713498A (en) 2017-07-28

Similar Documents

Publication Publication Date Title
CA2907924C (en) Telomerase mediated telomere altering compounds
ES2873893T3 (es) Métodos y composiciones para la inhibición específica de beta-catenina por RNA bicatenario
US11845938B2 (en) Aptamer compositions and the use thereof
PT2064327T (pt) Dbait e suas utilizações
PT1675954E (pt) Ácidos nucleicos úteis para induzir letalidade em células tumorais
ES3054091T3 (en) Asymmetric sirna for inhibiting expression of male pattern hair loss target gene
ES2620748T3 (es) Nuevos agonistas del receptor de tipo toll 3 y procedimientos de su utilización
JP7086039B2 (ja) ＮＯＴＣＨ １特異的なｓｉＲＮＡ分子
CA2980885C (en) Glycolipids and pharmaceutical compositions thereof for use in therapy
ES2464729T3 (es) Procedimientos y composiciones para la administración de 3-halopiruvato y compuestos relacionados para el tratamiento del cáncer
US10987428B2 (en) Phosphorothioate-conjugated miRNAs and methods of using the same
WO2025015097A1 (en) Dna-based proteolysis targeting chimera (sdtac) and methods of their use for treating diseases
JP2022520653A (ja) Ｃｙｐ２７ａ１の発現を阻害するための方法及び組成物
NZ732228B2 (en) Telomerase mediated telomere altering compounds
US20250136633A1 (en) Telomere-targeting phosphatidyl-thio conjugates
WO2020218494A1 (ja) ｍｉＲ３０２核酸改変体
US20240115594A1 (en) Dinucleotides and their use in treating cancer
US9617538B2 (en) Heptamer-type small guide nucleic acids inducing apoptosis of human leukemia cells
KR20130097585A (ko) 암치료 보조용 조성물
CN113930423A (zh) 保护心肌细胞免受应激损伤的saRNA及其应用
JP2009538272A (ja) オリゴマの改善された投薬およびスケジューリング